Intralesional Vitamin D3 for Anogenital Warts in Human Immunodeficiency Virus Infected Individual

Abstract

Anogenital warts (AGW) is the most common sexually transmitted infection in the world caused by the Human Papillomavirus (HPV), especially types 6 and 11. Immunotherapy is one of the therapeutic modalities that can be used to treat AGW. The mechanism of Vitamin D3 on AGW is the expression of antimicrobial peptides (AMP) that directly inactivate pathogens and also enhance innate immune responses. One case of AGW type condyloma acuminata was reported in a 29-year-old male. A case of condyloma acuminata-type AGW in a 29-year-old HIV stage 1 male patient was reported. His CD4 level was 500 cells/uL, and treated with anti-retroviral (ARV). Physical examination of the perianal area revealed a skin-colored tumor with a verrucous surface. Acetowhite test and HPV type 11 polymerase chain reaction (PCR) results were positive. The patient received intralesional injection of vitamin D3 60,000 IU per lesion every two weeks four times. The lesions appeared to have shrunk by more than 50% after the fourth injection. This case report shows the potential of intralesional vitamin D3 for the treatment of AGWs in an HIV patient. However, further research is required to confirm both the efficacy and safety of intralesional vitamin D3.